Toward Molecularly Driven Precision Medicine in Lung Adenocarcinoma. - PubMed - NCBI
2017 Jun;7(6):555-557. doi: 10.1158/2159-8290.CD-17-0355.
Toward Molecularly Driven Precision Medicine in Lung Adenocarcinoma.
<b/> Assessing the benefit of routine panel-based genomic sequencing of tumor tissue remains a critical need in clinical oncology. Jordan and coauthors report on 860 patients with metastatic or recurrent lung adenocarcinoma from a single institution with prospectively sequenced tumors using a targeted gene panel of >300 genes to guide therapy. Their results suggest that early prospective tumor sequencing, including non-standard-of-care predictive biomarkers combined with careful clinical annotation, can guide therapy, improve clinical outcomes, and accelerate the development of biomarkers and drugs. Cancer Discov; 7(6); 555-7. ©2017 AACRSee related article by Jordan et al., p. 596.
No hay comentarios:
Publicar un comentario